AM-Pharma, a biopharmaceutical company, has raised €29.2 million in series D venture capital financing. The investment round was led by Ysios Capital Partners and co-led by Kurma Life Science Partners.
The fundraising process was supported by a consortium, including the venture arms of Abbott and Shire, as well as existing investors Forbion Capital Partners and Inventages Venture Capital. Joël Jean-Mairet of Ysios, Remi Droller of Kurma Life Sciences Partners and Klaus Breiner of BB Biotech Ventures will be joining the supervisory board of AM-Pharma.
Click here for the release from Business Wire.